Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Jun 23, 2021 8:04am
112 Views
Post# 33433141

RE:Our new Board Member

RE:Our new Board MemberI dont think the awfull OO would have happened with this imaginative and competent and experienced New Board Member
Below is one of his accomplishment as described by one former partner

Frank Holler was a board member of Contech Enterprises from 2007 to 2010. During his tenure, he provided valuable insights which helped Contech double in size over three years. Specifically, he was able to help negotiate a complex transaction that combined an equity financing with the merging of two companies. One company required the buyout of a hostile founder and the other a reorganization and turnaround after the recent firing of its President. Frank’s understanding of the operating side of a business combined with his ability to relate to and effectively work with others played a large role in not just completing the complex transaction but building the company’s success in the following years. Working with Frank was a pleasure and I look forward to other opportunities to work with him in the future.
 

Frank Holler was a board member of Contech Enterprises from 2007 to 2010. During his tenure, he provided valuable insights which helped Contech double in size over three years. Specifically, he was able to help negotiate a complex transaction that combined an equity financing with the merging of two companies. One company required the buyout of a hostile founder and the other a reorganization and turnaround after the recent firing of its President. Frank’s understanding of the operating side of a business combined with his ability to relate to and effectively work with others played a large role in not just completing the complex transaction but building the company’s success in the following years. Working with Frank was a pleasure and I look forward to other opportunities to work with him in the future.
<< Previous
Bullboard Posts
Next >>